跳至主要内容
临床试验/NCT02557087
NCT02557087Unknown2 期

Efficacy of Intravenous Hyoscine ButylBromide as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial

Ain Shams Maternity Hospital0 个研究点目标入组 104 人开始时间: 2015年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
104
主要终点
The efficacy of intravenous tenoxicam to supply adequate analgesia as indicated by changes in the pain intensity score using the visual analog scale.

研究概览

简要总结

The aim of this study is to assess whether hyoscine butylbromide is as effective as pethidine for analgesia during the first stage of labor.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 30 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Primiparity
  • Active phase of labor (cervical dilatation of 3-5 cm, in the presence of adequate uterine contractions; lasting at least 40 seconds at intervals of 3-4 minutes)
  • Maternal age between 20-30 years
  • Singleton term pregnancy (37-42 weeks of gestation)
  • Vertex-presenting fetus

排除标准

  • Clinical evidence of cephalopelvic disproportion.
  • Scarred uterus; previous cesarean section, hysterotomy or myomectomy.
  • Any medical disorders associated with pregnancy.
  • Fetal distress
  • Receiving any regional or parenteral analgesia before recruitment in the study
  • Known hypersensitivity to the drug family

研究组 & 干预措施

Pethidine

Active Comparator

Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.

干预措施: Pethidine (Drug)

Hyoscine

Experimental

Intravenous administration of Hyoscine N-butylbromide diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.

干预措施: Hyoscine (Drug)

结局指标

主要结局

The efficacy of intravenous tenoxicam to supply adequate analgesia as indicated by changes in the pain intensity score using the visual analog scale.

时间窗: 4 hours

Assessment is to be done and followed up by the investigator at ½, 1, 2, 3 and 4 hours from drug administration. Scores range from 0 \[no pain\] to 10 \[worst possible pain\].

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hamdy Bakry Mohye Soliman El Kinawy

TA

Ain Shams Maternity Hospital

相似试验